Sep 30, 2011, 07.21 PM | Source: CNBC-TV18
SP Tulsian of sptulsian.com is positive on Ranbaxy Labs.
SP Tulsian (more)
CEO, sptulsian.com | Capital Expertise: Equity - Fundamental ,IPO
Tulsian told CNBC-TV18, “Ranbaxy Labs has corrected in last 15 days or so and it fell to about Rs 460-465 so I think maybe again the news of Lipitor and all sort of things, settlement with the US FDA both these two news are pending for quite a long time and if all these things happen, mainly the US FDA settlement the expected liability of USD 1 billion which was togged will get settled about USD 300-400 million.”
He further added, “So all those things are very much positive for the stock and in fact if you see lately in last couple of months the overseas promoter Dai-Ichi has become quite active and focused on this company and that indicates a positive view on the stock.”